TRVI
Trevi Therapeutics, Inc.
There isn't enough reported data to score TRVI yet.
TRVI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TRVI's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
TRVI PE Valuation
TRVI has no meaningful PE right now: it lost money over the past year.
TRVI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect TRVI's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
TRVI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.39 | -$0.02 |
| Q2 2026 | -$0.34 | +$0.08 |
| Q1 2026 | -$0.32 | +$0.13 |
| Q4 2025 | -$0.32 | +$0.15 |
| Q3 2025 | -$0.37 | +$0.07 |
| Q2 2025 | -$0.42 | -$0.03 |
| Q1 2025 | -$0.45 | -$0.11 |
| Q4 2024 | -$0.47 | -$0.18 |
TRVI is still losing money, but far less than before: $0.39 per share over the past year, against $1.84 at its worst in mid-2021.
TRVI Quarterly Revenue
TRVI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.7M | -$8.8M |
| Q1 2026 | -$16.8M | -$3.3M |
| Q4 2025 | -$7.6M | +$1.9M |
| Q3 2025 | -$10.9M | -$1.3M |
| Q4 2024 | -$9.6M | -$3.2M |
| Q3 2024 | -$9.6M | -$2.3M |
| Q4 2023 | -$6.4M | +$66K |
| Q2 2023 | -$9.9M | -$3.7M |
TRVI has burned cash in almost every quarter: −$62M over the past year, against −$43M the year before.
TRVI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +3.1M shares |
| 1 year | +10% | +14.6M shares |
| 3 years | +62% | +61M shares |
| 5 years | +723% | +140M shares |
| Available history | +796% | +142M shares |
TRVI has 160M diluted shares, up 10% from a year ago.
TRVI Net Leverage
TRVI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TRVI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 28.1 | Neutral |
TRVI's weekly RSI is 45 (neutral) and its Stochastic is 28 (neutral).
TRVI PE vs Healthcare Sector
TRVI has no meaningful PE right now: it lost money over the past year.
TRVI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.4 | 1.3% above |
| 20 week MA | $15.9 | 14% below |
| 50 week MA | $14.1 | 3.2% below |
| 100 week MA | $10.5 | 30% above |
| 200 week MA | $6.48 | 110% above |
TRVI's trend is mixed: it's above three of its five weekly moving averages, and 110% above its 200-week average.
TRVI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.72 | $2.79 | -25% |
| 2021 | $2.79 | $0.75 | -73% |
| 2022 | $0.75 | $1.79 | +139% |
| 2023 | $1.79 | $1.34 | -25% |
| 2024 | $1.34 | $4.27 | +219% |
| 2025 | $4.27 | $12.9 | +201% |
| 2026 YTD | $12.9 | $13.6 | +6% |
TRVI's yearly returns have swung widely, from +219% in 2024 to −73% in 2021. It's up 6% so far in 2026.